AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01484106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Resuscitation
Description: In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR).
Study NCT01484106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study NCT04735354 — intervention group
Intervention type: DRUG
Intervention: sacubitril/valsartan
Description: There was no treatment allocation. Patients administered sacubitril/valsartan by prescription that started before inclusion of the patient into the study were enrolled.
Study NCT03749473 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily performance feedback
Description: Participants will receive daily performance feedback on their daily step count.
Study NCT03749473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.
Study NCT00562471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adhibit Adhesion Prevention Gel
Description: A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
Study NCT00562471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Comparator
Description: standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
Study NCT06448078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External chest wall fixator
Description: External chest wall fixator is applied in the form of external bonding to the rib fracture area
Study NCT03605212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Intervention is orally administered to patients in this arm.
Study NCT03605212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Intervention is orally administered to patients in this arm.
Study NCT02083081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community level intervention
Description: Community intervention plus individual counseling
Study NCT02798146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood collection
Description: Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
Study NCT00537797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG-PET Scan
Description: Positron emission tomography with 18F-fluorodeoxyglucose
Study NCT01450631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena™ Incision Management System (PIMS)
Description: PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
Study NCT01450631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care Dressing
Description: The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
Study NCT01430715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active vido games and outdoor play
Description: Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, > 5th % to \< 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Telaprevir
Description: Initiation of a regimen containing TVR
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Boceprevir
Description: Initiation of a regimen containing BOC
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir
Description: Initiation of a regimen containing SOF
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Simeprevir
Description: Initiation of a regimen containing SMV
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Daclatasvir
Description: Initiation of a regimen containing DCV
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Ledipasvir
Description: Initiation of a regimen containing LDV
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: ritonavir-boosted Paritaprevir/ Ombitasvir
Description: Initiation of a drug combination of PTV/OTV
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Dasabuvir
Description: Initiation of a regimen containing DBV
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Velpatasvir
Description: Initiation of a regimen containing VPV
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Elbasvir
Description: Initiation of a regimen containing EBV
Study NCT02333292 — intervention group
Intervention type: DRUG
Intervention: Grazoprevir
Description: Initiation of a regimen containing GZR
Study NCT02344862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981 High dose, (Oral daily dosing for 8 weeks)
Description: Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
Study NCT02344862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981 Middle dose, (Oral daily dosing for 8 weeks)
Description: Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
Study NCT02344862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981 Low dose, (Oral daily dosing for 8 weeks)
Description: Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
Study NCT02344862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, (Oral daily dosing for 8 weeks)
Description: Subjects randomized to the placebo arm receive placebo.
Study NCT01024231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX1106-04)
Study NCT03223987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strath® Kräuterhefe Original (liquid)
Description: The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study.
Study NCT01111552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram oral capsules.
Study NCT01024231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01111552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole oral capsules.
Study NCT01111552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Study drug matching placebo capsule.
Study NCT04167891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Calculation of early prognosis score
Description: Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
Study NCT02097225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT02097225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02026908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate Artery Embolization
Description: Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
Study NCT01695980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETT with non modified retractor
Description: adenotonsillectomy
Study NCT01695980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LMA with modified retractor
Description: LMA with modified retractor
Study NCT00633139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human Arylsulfatase A (rhASA)
Description: intravenous infusion, every other week for 26 weeks
Study NCT00758927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 acid 4 grams per day
Description: OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
Study NCT02097225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV
Study NCT00758927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
Study NCT01815710 — intervention group
Intervention type: OTHER
Intervention: Pediatric Asthma Clinical Pathway
Description: Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
Study NCT01815710 — intervention group
Intervention type: OTHER
Intervention: Vomiting & Diarrhea Pathway
Description: Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
Study NCT02122861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID-LV305
Description: pembrolizumab
Study NCT02097225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02097225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT04619628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-VAC
Description: intranasal, live attenuated vaccine against SARS-CoV-2
Study NCT04619628 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study NCT01166698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9819
Description: Inhaled single doses of suspension via SPIRA nebuliser
Study NCT01166698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9819
Description: Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
Study NCT01166698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
Study NCT05259098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet System
Description: Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
Study NCT05259098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Patient-Controlled Analgesia with morfine
Description: Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
Study NCT04224740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab at the dose of 200mg IV Q3W with maximum duration of 2 years (34 cycles-counting the part combined with chemotherapy)
Study NCT04224740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care therapy
Description: Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
Study NCT01029288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Medication Choice Decision Aid
Description: Diabetes Medication Choice cards
Study NCT01029288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Statin Choice Decision Aid
Description: Statin Choice Cards
Study NCT01029288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for lipid therapy medication
Description: Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
Study NCT01029288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for antihyperglycemic medication
Description: Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
Study NCT03417284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT
Study NCT03417284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC
Study NCT03417284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given IV
Study NCT04617613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole, Amoxicillin, Metronidazole and Clarithromycin
Description: The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
Study NCT04617613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole, Amoxicillin and Clarithromycin
Description: The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
Study NCT00384540 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dobutamine stress echocardiography, coronarography, brachial arterial echography
Description: DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
Study NCT00089843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone patch 150mcg daily
Study NCT00089843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actonel (risedronate)
Description: Actonel (risedronate) 35mg PO one time weekly
Study NCT00089843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Actonel (risedronate)
Description: Placebo tablet identical in appearance to active Actonel (risedronate) tablet
Study NCT00089843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Actonel (risedronate)
Description: Placebo tablet identical in appearance to active Actonel (risedronate) tablet
Study NCT04576455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant is taken orally once per day on Days 1-28 of each 28-day cycle.
Study NCT04576455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant or an Aromatase Inhibitor (Physician Choice)
Description: Physician choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.
Study NCT00089843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo testosterone
Description: Placebo patch identical in appearance to testosterone patch
Study NCT00089843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo testosterone
Description: Placebo patch identical in appearance to testosterone patch
Study NCT02674997 — intervention group
Intervention type: BIOLOGICAL
Intervention: Factor VIII
Description: Licensed Factor VIII products. Study is brand agnostic
Study NCT01543490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-305
Description: Dexamethasone in DuraSite® 2 twice daily for 2 weeks
Study NCT01543490 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle twice daily for 2 weeks
Study NCT02075502 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise therapy
Description: The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
Study NCT02075502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
Study NCT02075502 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lower extremity ET
Description: catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
Study NCT04576455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study NCT00750386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2, I.V, every 2 weeks
Study NCT04576455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study NCT04862403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord clamping distance
Description: Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).
Study NCT02748798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP 3He
Description: 3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
Study NCT02748798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP 129Xe
Description: 129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.